Effect of Intravitreal Ranibizumab Injection With Retinal Vein Occlusion (RVO)

• Status: Completed
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effects of intravitreal Lucentis® (Ranibizumab) and investigate the anatomical and functional improvement following this treatment in patients with macular edema due to retinal vein occlusion (RVO).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Korea Ltd.
• Treatments: Ranibizumab

Criteria

Inclusion Criteria:

• Signed written informed consent

• Patients with macular edema due to RVO (confirmed by fundus photography, fluorescein angiography, OCT)

• Male and female aged from 18 to 70

• Baseline best-corrected visual acuity (BCVA) in the study eye was from 20/400 to 20/30 using ETDRS chart

Exclusion Criteria:

• Additional eye disease that could compromise VA

• Ocular inflammation

• Intraocular surgery ≤ 1 month before day 0

• Uncontrolled glaucoma

• Prior treatments with laser photocoagulation or other intervention for macular edema due to BRVO

• Patients aged under 18 or over 71

• Female patient in pregnancy or breast feeding

• Not suitable to regular follow up